Press Release – New York, NY – November 3, 2026 – Sichenzia Ross Ference Carmel LLP announced today that it represented INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, in its recent $4.5 million registered direct offering and concurrent private placement.
The SRFC team was led by partners Marc Ross, Tom Rose and Thiago Spercel, with counsel Tomer Magid and associate Jacob Horowitz.